Markets:

Overview

News

Currencies

International

Treasuries

Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

74.23 -0.18 (-0.24%)

Streaming Delayed Price Updated: 12:55 PM EDT, Jun 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Arrowhead Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Arrowhead Pharmaceuticals Receives Breakthrough Therapy Designation from U.S. FDA for ARO-AAT for the Treatment of Alpha-1 Antitrypsin Deficiency Associated Liver Disease

July 29, 2021

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals: Buy the Dip? ↗

July 19, 2021

This biotech underdog offers more than meets the eye.

Via The Motley Fool

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Third Quarter Results

July 14, 2021

From Arrowhead Pharmaceuticals Inc.

Via Business Wire

Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

July 14, 2021

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Russell 2000 Traders Place Bearish Bets Via IWM ETF ↗

July 13, 2021

The iShares Russell 2000 ETF (NYSE: IWM) has been trading sideways for the better part of the last six months between $211 and its all-time high of $234.53 from March 15. IWM...

Via Benzinga

Arrowhead's Big Sell-Off Presents Buying Opportunity, According to HC Wainwright ↗

July 06, 2021

The sell-off on shares of Arrowhead Pharmaceuticals Inc (NASDAQ:

Via Benzinga

Arrowhead's ARO-HIF2 Shows Early Signs Of Efficacy In Type Of Kidney Cancer ↗

July 06, 2021

Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) has announced interim results from the first two cohorts of Phase 1b study of ARO-HIF2 for clear cell renal cell...

Via Benzinga

Arrowhead Announces Positive Interim Results from Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma

July 06, 2021

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

56 Biggest Movers From Friday ↗

July 06, 2021

Gainers Sequential Brands Group, Inc. (NASDAQ: SQBG) jumped 89.2% to settle at $15.70. Eco Wave Power Global AB (NASDAQ: WAVE) shares surged 73.2% to close at $18.79. A 13G...

Via Benzinga

Mid-Afternoon Market Update: Silver Rises 2%; Alector Shares Spike Higher ↗

July 02, 2021

Toward the end of trading Friday, the Dow traded up 0.46% to 34,792.90 while the NASDAQ rose 0.67% to 14,619.12. The S&P also rose, gaining 0.66% to 4,348.47. The U.S. has the...

Via Benzinga

Topics Stocks

S&P 500 Logs Another Record High as "Fear Gauge" Dips ↗

July 02, 2021

Stocks are modestly in the black midday, thanks to upbeat monthly jobs data that showed 850,000 jobs were added in June.

Via Talk Markets

Topics Stocks

12 Health Care Stocks Moving In Friday's Intraday Session ↗

July 02, 2021

Gainers Alector (NASDAQ:ALEC) shares moved upwards by 52.47% to $34.17 during Friday's regular session. Alector's stock is trading at a volume of 26.9 million...

Via Benzinga

Arrowhead Stock Plunges, Alector Stock Surges On Drug News ↗

July 02, 2021

Arrowhead paused a drug study; Alector teamed up with GlaxoSmithKline to develop two drugs. Arrowhead stock sank, while Alector stock surged.

Via Investor's Business Daily

Mid-Day Market Update: Dow Surges Over 100 Points; Arrowhead Pharmaceuticals Shares Plummet ↗

July 02, 2021

Midway through trading Friday, the Dow traded up 0.33% to 34,747.45 while the NASDAQ rose 0.50% to 14,594.85. The S&P also rose, gaining 0.47% to 4,340.12. The U.S. has the...

Via Benzinga

Topics Stocks

Here's Why Arrowhead Pharmaceuticals Stock Is Getting Hammered Today ↗

July 02, 2021

A paused clinical trial with an important asset wasn't what investors wanted to hear today.

Via The Motley Fool

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

July 02, 2021

Gainers Alector (NASDAQ:ALEC) stock moved upwards by 39.93% to $31.36 during Friday's pre-market session. The market value of their outstanding shares is at $2.5...

Via Benzinga

Arrowhead Stock Drops After RNAi Therapeutic Shows Lung Inflammation In Animal Models ↗

July 02, 2021

Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) has voluntarily paused the AROENaC1001 Phase 1/2 study evaluating ARO-ENaC for cystic fibrosis. ARO-ENaC is the...

Via Benzinga

Arrowhead Pauses ARO-ENaC Phase 1/2 Clinical Study

July 02, 2021

From Arrowhead Pharmaceuticals Inc.

Via Business Wire

Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-ANG3 for Treatment of Mixed Dyslipidemia

June 30, 2021

From Arrowhead Pharmaceuticals Inc.

Via Business Wire

Arrowhead Presents Additional Clinical Data on Investigational ARO-AAT Treatment in Patients with Alpha-1 Liver Disease at EASL International Liver Congress

June 26, 2021

From Arrowhead Pharmaceuticals Inc.

Via Business Wire

Arrowhead Presents Preclinical Data on ARO-DUX4 at FSHD Society International Research Congress

June 25, 2021

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO ↗

June 24, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) AngioDynamics, Inc. (NASDAQ...

Via Benzinga

Arrowhead Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH at EASL International Liver Congress

June 23, 2021

From Arrowhead Pharmaceuticals Inc.

Via Business Wire

Horizon Acquires Rights to Arrowhead's RNAi-Based Gout Treatment Candidate ↗

June 21, 2021

Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) and Horizon Therapeutics plc (NASDAQ: HZNP) have entered into a global collaboration and license agreement ...

Via Benzinga

Arrowhead Pharmaceuticals and Horizon Therapeutics Announce Collaboration to Develop RNAi Therapeutic for Uncontrolled Gout

June 21, 2021

From Arrowhead Pharmaceuticals, Inc. and Horizon Therapeutics plc

Via Business Wire

The Week In Charts - Why You Can't Trade, Or Maybe You Can? ↗

June 18, 2021

In this video, I look at the reasons for why you may or may not be able to trade. I also continue my discussion on finding

Via Talk Markets

Biotech Movers During ASCO Week ↗

June 12, 2021

The biotech sector performed well in a good ASCO week. And many biotech stocks were movers this week as a bullish sentiment took hold sparked by the Biogen Aduhelm approval.

Via Talk Markets

Vertex Pharma Stumbles In Rare-Disease Effort, Buoying Rival Arrowhead Pharma ↗

June 10, 2021

Vertex Pharmaceuticals scrapped development of a rare-disease treatment Thursday that appeared unlikely to benefit patients, and VRTX stock plunged.

Via Investor's Business Daily

Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-APOC3 for Treatment of Severe Hypertriglyceridemia

June 03, 2021

From Arrowhead Pharmaceuticals Inc.

Via Business Wire

Arrowhead Pharmaceuticals to Participate in Upcoming Conferences

June 02, 2021

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.